Fosun Pharma achieves steady growth in 2021

Under the guidance of the "4IN" (Innovation, Internationalization, Integration, Intelligentization) strategy, Fosun Pharma continues to adhere to the business philosophy of "Continuous Innovation, Enjoying Health", continuously promote innovation and transformation, and comprehensively accelerate internationalization At the same time, it will strengthen the integration of R&D, supply chain, production and commercialization systems, promote the improvement of enterprise operation quality and operation efficiency, and achieve steady growth in performance

During the reporting period, Fosun Pharma achieved an operating income of 39.

Increase investment in innovation and research and development, continue to promote innovation and transformation

Fosun Pharma takes innovative research and development as the core driving factor, and builds and forms small molecule innovations around key disease areas such as tumor and immune regulation, metabolism and digestive system, and central nervous system through independent research and development, cooperative development, licensing introduction, and deep incubation .

During the reporting period, Fosun Pharma continued to increase investment in innovation and research and development.

The pharmaceutical business R&D investment was 4.

As at the end of the reporting period, the Group had more than 2,800 R&D personnel, of which more than 1,500 held a master's degree or above, accounting for approximately 7.

After more than ten years of continuous investment, in the past three years, Hanlikang, Hanquyou, Su Kexin, Fubitai (mRNA new crown vaccine) and other varieties have been approved and sold in large quantities.

During the reporting period, the self-developed product Hanlikang (rituximab injection) achieved revenue of 1.

The mRNA new crown vaccine Fubitai, jointly developed by Fosun Pharma and Germany's BioNTech, was included in the Hong Kong and Macau government vaccination plan in March 2021, and will be vaccinated in Taiwan, China in September 2021

In June 2021, Fosun Pharma’s joint venture, Fosun Kite’s Yikaida (Aquilence Injection), became the first CAR-T cell therapy product approved for marketing in China, bringing benefits to second-line and above lymphoma patients.

In addition, Fosun Pharma's innovative pipeline continues to land, and the first indication of the PD-1 inhibitor slulimumab has been included in the priority review process for the registration application for the first indication of solid tumors with high microsatellite instability (MSI-H).

Continue to strengthen global operation and full capacity building and further enhance global operation capacity

Through a forward-looking global layout, Fosun Pharma has initially formed a global operation system for R&D, production and commercialization, and has continued to develop overseas markets to comprehensively accelerate the globalization process

As of the end of the reporting period, Fosun Pharma had an overseas commercialization team of more than 1,200 people.

Relying on the existing international production level and quality system certification of YaoPharma, Guilin Nanyao, Wanbang Pharmaceutical, etc.

As of January 2022, the total number of antimalarial products of Fosun Pharma that has passed the WHO-PQ has increased to 30, including 26 preparation products and 4 API products, which is the world's largest number of antimalarial drugs that have passed this certification.
business
.

Accelerate strategic upgrade and internal integration to drive business to achieve branch focus

In 2021, Fosun Pharma will actively promote the integration of systems and resources such as R&D, supply chain, production and marketing, so as to enhance synergy and operational efficiency, and promote steady growth in performance
.
During the reporting period, the core pharmaceutical business achieved operating income of 28.
904 billion yuan; the medical device and medical diagnosis business achieved operating income of 5.
938 billion yuan; the medical and health service business achieved operating income of 4.
118 billion yuan
.

During the reporting period, Fosun Pharma strengthened the supply chain management, accelerated the construction of competitive production bases, and promoted the strategic integration of the production side by sorting out the internal advantageous production capacity of the pharmaceutical sector
.
And at the beginning of 2022, the pharmaceutical business will be upgraded and divided into innovative drug business unit, generic drug and manufacturing business unit and vaccine business unit
.

During the reporting period, the medical device and medical diagnosis business continued to strengthen its independent operation capability
.
Through business integration and sorting out, the medical device sector has initially formed three major businesses centered on medical beauty, respiratory health, and professional medical care.
Among them, the core medical beauty platform Sisram is actively expanding the original energy source beauty equipment business.
At the same time, the layout of strategic tracks such as cosmetic dentistry, injection filling, and personal care will be carried out to accelerate the construction of medical beauty ecology
.

During the reporting period, Fosun Pharma completed the sorting out of the medical diagnosis business, initially realized the integration of operations, matched the strategic layout of the medical diagnosis business, completed the acquisition of Suzhou Baidao, laid out the pathological diagnosis, and enriched the track layout of the diagnosis business
.
The medical diagnosis business has formed a cross-methodology product portfolio around the six major disease areas of tumor, infection, digestion and metabolism, large reproductive, cardiovascular and cerebrovascular, and central nervous system, as well as a matrix R&D idea of ​​extending the same methodology to different disease areas
.

Deeply practice corporate social responsibility and pursue sustainable development

Fosun Pharma has always regarded sustainable development as an important indicator of corporate operations, and has released corporate social responsibility reports for 14 consecutive years, showing stakeholders the company's practices and achievements in the field of social responsibility
.
The "2020 Corporate Social Responsibility Report" released in March 2021 was rated as a five-star report (excellent) by the China Corporate Social Responsibility Report Rating Expert Committee
.
At the same time, Fosun Pharma continued to improve its ESG management level and promote the sustainable development of ESG.
The MSCI ESG rating was upgraded from "BB" to "BBB"
.

Wu Yifang, Chairman and CEO of Fosun Pharma, said, "In the context of the normalization of the COVID-19 epidemic, Fosun Pharma has continued to promote innovation and transformation and global capacity building.
In 2021, it will achieve steady growth in performance and continue to optimize its revenue structure
.
Focusing on epidemic prevention and control To control demand, Fosun Pharma has accelerated the technological innovation of anti-epidemic-related products to ensure the supply of anti-epidemic materials and strategic products
.
Facing the future, Fosun Pharma will continue to adhere to the 4IN (ie innovation, internationalization, integration, intelligence) strategy, focusing on future Actively deploy new technologies and products in the therapeutic areas that meet the needs, connect global outstanding scientific talents through diversified and multi-level cooperation models such as independent research and development, cooperative development, licensing introduction and in-depth incubation, and promote the development and implementation of innovative technologies and products
.
, Based on the existing advantages of medical resources and the Internet platform, actively explore the online and offline integrated service model, and promote the transformation of the medical Internet
.
"

***

About Fosun Pharma

Shanghai Fosun Pharma (Group) Co.
, Ltd.
("Fosun Pharma", stock code: 600196.
SH, 02196.
HK) was established in 1994.
It is a global pharmaceutical and health industry group rooted in China and driven by innovation.
The operating business includes pharmaceuticals, medical devices and medical diagnosis, medical and health services, and covers the pharmaceutical business field through the participation in Sinopharm Holding
.

Fosun Pharma is patient-centered and clinical needs-oriented, and enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, licensing introduction, and deep incubation
.
Focusing on key disease areas such as tumor and immune regulation, metabolism and digestive system, and central nervous system, Fosun Pharma has built and formed technology platforms for small molecule innovative drugs, antibody drugs, and cell therapy, and actively explores RNA, oncolytic viruses, and gene therapy.
, targeted protein degradation and other cutting-edge technologies to enhance innovation capabilities
.

Under the guidance of the "4IN" (Innovation, Internationalization, Integration, Intelligentization) strategy, Fosun Pharma will adhere to the development model of "innovative transformation, integrated operation, and steady growth" and the belief in creating value for shareholders.
Continuously strengthen innovative R&D and license introduction capabilities, enrich product lines, and strengthen globalization
.

For more information about the company, please visit the official website: .

Forward-Looking Statements:

This press release contains forward-looking statements
.
Except for the statements of historical fact contained in this press release, all discussions including, but not limited to, the Company's business strategy, future operations, profit margins, profitability, liquidity and capital resources, future developments in the Company's industry and the general economy of key markets A discussion of expectations for future developments, and any preceding, subsequent or including terms such as "expect," "seek," "believe," "plan," "intend," "estimate," "project," "anticipate," " Similar words or statements regarding the company or its management, such as "may" and "will," are intended to identify forward-looking statements
.
These statements are subject to certain known and unknown risks, uncertainties and assumptions that could cause the company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements
.
Accordingly, you should not place undue reliance on any forward-looking information
.
The Company does not undertake and undertakes no obligation to update or otherwise revise the forward-looking statements in this press release, whether as a result of new information, future events or developments or otherwise, as required by applicable laws, rules and regulations
.
In this press release, statements or references to the company's intent are effective as of the date of this press release
.
Any such intentions may change with future developments
.
All forward-looking statements contained in this press release are qualified by reference to the above cautionary statement
.